TRCT
AVIR icon

Tower Research Capital (TRC)’s Atea Pharmaceuticals AVIR Stock Holding History

Tower Research Capital (TRC)’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.8K Buy
6,203
+2,244
+57% +$11.2K ﹤0.01% 3216
2026
Q1 		$21.3K Buy
3,959
+1,269
+47% +$5.83K ﹤0.01% 3439
2025
Q4 		$9.6K Sell
2,690
-2,635
-49% -$8.37K ﹤0.01% 3888
2025
Q3 		$15.4K Sell
5,325
-3,167
-37% -$10.8K ﹤0.01% 3539
2025
Q2 		$30.6K Sell
8,492
-12,944
-60% -$38.6K ﹤0.01% 3385
2025
Q1 		$64.1K Buy
21,436
+17,819
+493% +$55.6K ﹤0.01% 2047
2024
Q4 		$12.1K Sell
3,617
-8,117
-69% -$27K ﹤0.01% 3649
2024
Q3 		$39.3K Buy
11,734
+2,252
+24% +$8.17K ﹤0.01% 2857
2024
Q2 		$31.4K Buy
9,482
+8,012
+545% +$29.9K ﹤0.01% 3457
2024
Q1 		$5.94K Sell
1,470
-28,870
-95% -$113K ﹤0.01% 4463
2023
Q4 		$92.5K Buy
30,340
+17,042
+128% +$51.6K ﹤0.01% 2706
2023
Q3 		$39.9K Buy
13,298
+7,552
+131% +$25.7K ﹤0.01% 2743
2023
Q2 		$21.5K Buy
5,746
+2,590
+82% +$9.7K ﹤0.01% 3327
2023
Q1 		$11K Sell
3,156
-17,888
-85% -$72.6K ﹤0.01% 4183
2022
Q4 		$101K Buy
21,044
+3,239
+18% +$16.4K ﹤0.01% 1830
2022
Q3 		$102K Sell
17,805
-5,697
-24% -$43.6K ﹤0.01% 2547
2022
Q2 		$167K Buy
23,502
+22,203
+1,709% +$152K ﹤0.01% 1910
2022
Q1 		$9K Buy
1,299
+46
+4% +$312 ﹤0.01% 4432
2021
Q4 		$11K Sell
1,253
-5,336
-81% -$83.2K ﹤0.01% 4384
2021
Q3 		$231K Buy
6,589
+4,908
+292% +$136K 0.01% 1681
2021
Q2 		$36K Buy
1,681
+952
+131% +$28.6K ﹤0.01% 3294
2021
Q1 		$45K Buy
729
+397
+120% +$26.8K ﹤0.01% 3208
2020
Q4 		$14K Buy
+332
New +$10.7K ﹤0.01% 4088

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Tower Research Capital (TRC)'s AVIR Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Atea Pharmaceuticals (AVIR) stake by 57% in Q2 2026, buying an estimated $11.2K and bringing the position to 6,203 shares worth $28.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3216.

Tower Research Capital (TRC) first reported a position in AVIR in Q4 2020 and has held it in 23 quarters since. The position peaked at $231K in Q3 2021. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Tower Research Capital (TRC) held 6,203 shares of Atea Pharmaceuticals worth $28.8K as of Q2 2026.
  • Tower Research Capital (TRC) bought 2,244 Atea Pharmaceuticals shares in Q2 2026, an estimated $11.2K.
  • Atea Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3216 holding.
  • Tower Research Capital (TRC) first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Tower Research Capital (TRC)'s Atea Pharmaceuticals position peaked at $231K in Q3 2021.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.